Table 7.

Analysis of pro- and anti-inflammatory markers (RRT at 1 year)

Patients without RRT at 1 yr, d0Patients with RRT at 1 yr, d0P ValuePatients without RRT at 1 yr, d3Patients with RRT at 1 yr, d3P Value
MIF, median (Q1, Q3), pg/ml16,488.6 (10,100.7, 42,386.4)12,100.8 (8103.0, 56,378.1)0.6810,882.8 (4828.2, 15,916.2)6588.0 (2620.2, 35,932.2)0.79
IL-6, median (Q1, Q3), pg/ml957.3 (295.3, 1697.0)2175.0 (1044.4, 2339.1)0.12257.6 (100.9, 595.6)696.5 (82.0, 764.2)0.65
IL-8, median (Q1, Q3), pg/ml255.2 (93.7, 553.5)334.6 (111.0, 461.8)0.9464.2 (28.4, 125.4)51.4 (13.6, 97.6)0.49
IL-10, median (Q1, Q3), pg/ml44.4 (20.8, 129.4)26.3 (10.0, 98.6)0.2716.5 (8.9, 37.2)15.3 (14.2, 33.8)0.85
IL-18, median (Q1, Q3), pg/ml597.0 (348.6, 1220.5)288.8 (194.6, 1179.2)0.11539.1 (290.5, 1455.0)747.5 (395.9, 1201.8)0.69
TNFR-1, median (Q1, Q3), pg/ml1707.6 (1205.7, 2202.4)1505.0 (866.0, 2926.2)0.801550.7 (943.1, 2411.1)2125.0 (990.2, 3217.7)0.50
TNFR-2, median (Q1, Q3), pg/ml21,180.0 (14,844.9, 26,980.0)19,477.1 (9258.5, 28,190.0)0.5122,080.0 (12,481.9, 31,440.0)18,222.2 (10,872.8, 30,900.0)0.51
  • Patients who died within 1 year are excluded; n=8 patients with RRT at 1 year. d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.